International Journal of Hematology and Oncology 2019, Vol 29, Num 3 Page(s): 208-211
CURRENT MANAGEMENT OF UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER

Özden ALTUNDAĞ1, Kadri ALTUNDAĞ2,3

1Department of Thoracic/Head&Neck Cancer Medicine The University of Texas M .D. Anderson Cancer Center, Houston, Texas, USA
2Hacettepe Üniversitesi Tıp Fakültesi İç Hastalıkları Anabilim Dalı, Medikal Onkoloji Bölümü, ANKARA
3Department of Breast Medical Oncology The University of Texas M .D. Anderson Cancer Center, Houston, Texas, USA

Keywords: Stage III Lung cancer, Unresectable, Chemotherapy, Radiotherapy
Approximately 20-25% of non-small cell lung cancer (NSCLC) patients initially present with stage III disease. Since locoregional recurrences and even more so, distant metastasis are common, overall survival rate is poor. Treatment aims in stage III NSCLC are to improve both local and systemic control of disease. Therefore patients with stage III disease should be treated with therapy intended to decrease both locoregional failure and micrometastatic disease. Systemic therapy given together with radiation eliminates the need to make a choice about which to delay, systemic or local therapy. The role of chemotherapy with thoracic radiation has been extensively investigated in unresectable stage III NSCLC. Recent studies suggest that chemotherapy and radiotherapy are more efficacious when given concurrently. Thus concurrent chemoradiotherapy has been a standard therapy for selected patients with locally advanced unresectable NSCLC. Together, the induction and consolidation studies suggest that improved distant and local control are important strategies to use to improve survival in stage III NSCLC. However, despite these improvements, most patients will still recur and die with stage III disease and new strategies are needed.